Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/13/2008US20080280917 Nitrogen-Containing heterocyclyl ketones and methods of use
11/13/2008US20080280916 treating and/or preventing skin disorders mediated by stearoyl-CoA desaturase in mammals selected from acne, rosacea and seborrheic skin, comprising administering 6-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (2-phenoxyethyl)amide
11/13/2008US20080280914 Intravenous Formulations of Pde Inhibitors
11/13/2008US20080280913 dipeptidyl-peptidase IV (DPP-IV) inhibitors such as 5,5,6,6,8,8-d6-3-(trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine; increasing hormone glucagon-like peptide levels; pharmacokinetics; side effect reduction
11/13/2008US20080280912 Diagnosis test; mixing blood or other fluid sample with test compound; analyzing, calibration; central nervous system disorders; analgesics; antiinflamamtory agents; drug abuse; anxiolytic agents; cognition activators;Alzheimer's disease; Parkinson's disease; Huntington's disease; hyperactivity
11/13/2008US20080280911 Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4)
11/13/2008US20080280910 Phthalazinone derivatives
11/13/2008US20080280909 New phenylalanine derivatives
11/13/2008US20080280908 N-(2-(7-(methoxy-d3)-naphthalen-1-yl)ethyl)acetamide-d3, a deuterated derivative of Agomelatine; side effect reduction; decreased metabolic liability; pharmakinetics; bioavailability;antidepressants; anxiolytic agents; bipolar disorders; dual melatoninergic agonist and serotoninergic antagonist
11/13/2008US20080280907 Triazolophthalazines
11/13/2008US20080280906 Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders
11/13/2008US20080280905 Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
11/13/2008US20080280904 N-Substituted Pyridinone or Pyrimidinone Compounds Useful as Soluble Epoxide Hydrolase Inhibitors
11/13/2008US20080280903 antiapoptosis agents such as 1-[2-Methoxyimino-2-(4-pyrrolidin-1-yl-phenyl)-ethyl]-quinolinium bromide, used for cytoprotection or for side effect reduction of anticarcinogenic agents
11/13/2008US20080280902 Inhibitors of Checkpoint Kinases
11/13/2008US20080280901 Pharmaceutical Composition for Preventing and Treating Metabolic Bone Diseases Containing Alpha-Arylmethoxyacrylate Derivatives
11/13/2008US20080280900 Bicyclic pyrimidine derivatives as calcium channel blockers
11/13/2008US20080280899 Cancer; such as 3-({4-[2-(methylthio)-6-phenylpyrido[2,3-d]pyrimidin-7-yl]benzyl}amino)-1-phenylpropan-1-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity
11/13/2008US20080280898 5-Bromo-1'-[(3-methyl-1H-inden-2-yl)carbonyl]spiro[indole-3,4'-piperidin]-2(1H); vasopressin receptor antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder
11/13/2008US20080280897 Aerosol Formulation for Inhalation
11/13/2008US20080280896 Dipyrrole Compounds, Compositions, and Methods For Treating Cancer or Viral Diseases
11/13/2008US20080280895 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension
11/13/2008US20080280894 DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
11/13/2008US20080280893 SUBSTITUTED-DIHYDRO[1,4]OXAZINO[2,3,4-hi]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
11/13/2008US20080280892 Tricyclic nitrogen antibacterial; 1-({4-[(2,3-Dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amino]-1-piperidinyl}methyl)-9-fluoro-1,2-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-4-one; may be used with other active ingredients, diluents
11/13/2008US20080280891 effective against a broad range of cancers, especially leukemia, non-small cell lung and colon; (6-chloropyridin-3-yl)-[3-hydroxy-5-(1H-indol-4-yl)-phenyl]-methanone; antimitotic agents that can block cell cycle progression
11/13/2008US20080280890 Hydroxylamine compounds and methods of their use
11/13/2008US20080280889 Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties
11/13/2008US20080280888 Antibiotics Derivatives
11/13/2008US20080280887 Selected Cgrp-Antagonists, Processes for Preparing Them and Their Use as Pharmaceutical Compositions
11/13/2008US20080280886 Substituted ureas
11/13/2008US20080280885 Methods for Treating Anxiety Related Disorders
11/13/2008US20080280884 Mixed Solvate of Olanzapine, Method for Preparing It and Method for Preparing Form I of Olanzapine Therefrom
11/13/2008US20080280883 Muscarinic Receptor Antagonists
11/13/2008US20080280882 Novel Substituted Diazabicyclo Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors
11/13/2008US20080280881 Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication
11/13/2008US20080280880 Staurosporine Derivatives for Use in Alveolar Rhabdomyosarcoma
11/13/2008US20080280879 Substituted heterocyclic derivatives and their pharmaceutical use and compositions
11/13/2008US20080280878 Blocking HSP90, particularly ansamycin or 17-allylamino-17-demethoxygeldanamcin; controlling gene expression; tyrosine lkinase inhibitor
11/13/2008US20080280877 Azetidines
11/13/2008US20080280876 Sphingosine-1-phosphate (S1P) receptor agonists or antagonists; immunosuppressants; e.g. 3-(3-chloro-4-isopropoxyphenyl)-5-(p-(3-carboxyazetidin-1-ylmethyl)phenyl)-1,2,4-oxadiazole; two specific compounds are excluded
11/13/2008US20080280875 Fused phenyl amido heterocyclic compounds
11/13/2008US20080280874 Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity
11/13/2008US20080280873 Biaryl Substituted Pyrazinones as Sodium Channel Blockers
11/13/2008US20080280872 Benzamide Derivatives and Their Use as Glucokinase Activating Agents
11/13/2008US20080280871 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases
11/13/2008US20080280870 Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists
11/13/2008US20080280869 Therapy for diseases resulting from mutation of messenger Rna; suppression prenature translation termination; autoimmune diseases; blood disorders; collagen disease; diabetes; neurodegenerative diseases; cardiovascular disorders; central nervous system disorders; antiinflammatory agents
11/13/2008US20080280868 Pyridine Derivatives and Their Use as Cb2 Receptor Modulators
11/13/2008US20080280867 temozolomide and veliparib for prostate cancer
11/13/2008US20080280866 Administering to animal for risk of inflammatory damage to organs from trauma or sepsis a calcium channel moderator and kinase inhibitor
11/13/2008US20080280864 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme )
11/13/2008US20080280863 Concurrent administering by mouth a corticosteroid and tricyclic antidepressant compound; immunoinflamamtory disorders; antiarthritic agents; skin disorders; inflammatory bowel disorders; Crohn's disorders; autoimmune disease; asthma; multiple sclerosis; diabetes; lupus
11/13/2008US20080280862 Methods, compositions, and kits for the treatment of pain
11/13/2008US20080280861 Alternation of preservation and shredding phase; continuous administering, for preservation stage, by mouth dosage of estrogen and progesterone such as norgestrel for three to twelve month cycle; then for shredding phase not administering drugs
11/13/2008US20080280860 Administering a vitamin d compound with carrier; urogenital pain; sun-fertility
11/13/2008US20080280859 Gemini vitamin d3 compounds and methods of use thereof
11/13/2008US20080280858 Method of creating crystalline substances
11/13/2008US20080280857 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
11/13/2008US20080280856 Fibroblast Activation Protein Inhibitor Compounds and Methods
11/13/2008US20080280855 Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles
11/13/2008US20080280854 Preventing or reducing oxidative stress or oxidative cell injury
11/13/2008US20080280853 Compositions for reducing, ameliorating, treating, or preventing condition of dry eye and methods of making and using same
11/13/2008US20080280852 Composition Containing Fermentable Polysaccharides
11/13/2008US20080280851 Oral Dosage Forms of Gemcitabine Derivatives
11/13/2008US20080280850 administering an effective viriuses treatment amount of a base-modified nucleoside or a salt or prodrug for treating a host infected with flavivirus, pestivirus or hepacivirus
11/13/2008US20080280849 Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
11/13/2008US20080280848 Structures of Active Guide Rna Molecules and Method of Selection
11/13/2008US20080280847 small interfering RNAs (siRNAs) to identify nucleotides encoding proteins involved in the co-transport of inorganic phosphate in vascular tissues; therapeutics
11/13/2008US20080280846 2', 3'-dideoxynucleoside analogues for the treatment or prevention of flaviviridae infections
11/13/2008US20080280845 an antisense compound that hybridizes with a nucleic acid molecule that expreses PTPRU ( protein tyrosine phosphatase receptor type U), thereby inhibiting the expression of the nucleic acid molecule; treatment of diabetes, obesity, insulin resistance, insulin deficiency, hypercholesterolemia etc.
11/13/2008US20080280844 Methods and compositions for the diagnosis and treatment of ewing's sarcoma
11/13/2008US20080280843 Methods and kits for linking polymorphic sequences to expanded repeat mutations
11/13/2008US20080280842 Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection
11/13/2008US20080280841 Amorphous Telithromycin Compound
11/13/2008US20080280840 Meloxicam for the treatment of respiratory diseases in pigs
11/13/2008US20080280839 Anticancer agent saxifragifolin D, saxifragifolin B
11/13/2008US20080280838 Composition Containing Ginsenoside F1 and Egcg for Preventing Skin Damage
11/13/2008US20080280837 Biologically Active Compounds with Anti-Angiogenic Properties
11/13/2008US20080280836 novel cholesterol absorption inhibitors; 1-phenyl-2-(p-benzylphenyl)-3-substituted azetidin-4-ones
11/13/2008US20080280829 Inhibition of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2); osteoporosis, osteopenia; use of 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)-aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one
11/13/2008US20080280828 Compositions Comprising Igbpma and Uses Thereof
11/13/2008US20080280826 for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors.
11/13/2008US20080280823 Treatment of Non-Alcoholic Steatotic Hepatitis (Nash)
11/13/2008US20080280822 Nucleic acid and corresponding protein entitled 161P5C5 useful in treatment and detection of cancer
11/13/2008US20080280817 Modified amino acid is N-(-5-chlorosalicyloyl)-8-aminocaprylic acid; active agents are heparin, insulin, parathyroid hormone, calcitonin; cardiovascular disorders
11/13/2008US20080280816 Methods and pharmaceutical compositions for healing wounds
11/13/2008US20080280815 Lowering Serum Lipids
11/13/2008US20080280813 Complex drug delivery composition and method for treating cancer
11/13/2008US20080280759 6-(2-Fluoro-4-Alkoxyphenyl) Triazolopyrimidines, Their Preparation, Their Use For Controlling Harmful Fungi, and Compositions Comprising Them
11/13/2008US20080280288 Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug
11/13/2008US20080279963 Aqueous isotonic solution of hypohalous acid and halide salt; acidity pH; storage stability; active against three types of Staphlococcus
11/13/2008US20080279962 Removal excess iron from blood; using a compound such as 4-(3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl)benzoic acid
11/13/2008US20080279961 Telomere targeting agents as stem cells directed treatments
11/13/2008US20080279955 Pharmaceutical microparticles
11/13/2008US20080279954 Drug delivery; therapeutic agent and crosslinked polymer network
11/13/2008US20080279952 Controlling particle size; overcoating particles; pain therapy eith postoperative or tumor pain; central nervous system disorders; antiepileptic agents; Parkinson's disease; longQT syndrome; potassium channel moderators; muscular disorders; prion disease; Alzheimer's disease; tinnitus ; overactive bladde
11/13/2008US20080279951 Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
11/13/2008US20080279950 Nano-particles comprising cucurbituril derivatives, pharmaceutical composition containing the same, and process for the preparation thereof
11/13/2008US20080279949 Such as paclitaxel and stabilizer
1 ... 2998 2999 3000 3001 3002 3003 3004 3005 3006 3007 3008 3009 3010 3011 3012 3013 3014 3015 3016 3017 3018 ... 7860